Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Drug-drug interactions

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    79 result(s) found for: Drug-drug interactions. Displaying page 2 of 4.
    « Previous 1  2  3  4  Next»
    EudraCT Number: 2006-001595-20 Sponsor Protocol Number: CRAD001J2102 Start Date*: 2006-11-23
    Sponsor Name:NOVARTIS FARMA
    Full Title: A phase Ib study investigating the combination of RAD001 with trastuzumab and vinorelbine in patients with HER2- overexpressing metastatic breast cancer
    Medical condition: HER2 overexpressing metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021977 Inflammatory carcinoma of breast recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003208-11 Sponsor Protocol Number: CRF002 Start Date*: 2020-03-04
    Sponsor Name:Chelsea and Westminster Hospital NHS Foundation Trust
    Full Title: Efficacy of BIC/F/TAF versus standard of care in the treatment of new HIV infection diagnoses in the context of 'test and treat'
    Medical condition: Human Immunodeficiency Virus (HIV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020441 Human immunodeficiency virus infection, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2018-002063-26 Sponsor Protocol Number: CAIN457M2301 Start Date*: 2019-01-16
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of 2 subcutaneous secukinumab dose regimens in adult patient...
    Medical condition: hidradenitis suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) DE (Completed) PT (Completed) HU (Completed) SK (Completed) CZ (Completed) BE (Completed) GR (Completed) AT (Completed) SE (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023183-40 Sponsor Protocol Number: CSOM230I2201 Start Date*: 2011-06-28
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, open-label phase II multicenter study evaluating the efficacy of oral Everolimus alone or in combination with Pasireotide LAR i.m. in advanced progressive pancreatic neuroendocrine tu...
    Medical condition: advanced progressive pancreatic neuroendocrine tumors (PNET)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067517 Pancreatic neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) DK (Prematurely Ended) DE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022534-84 Sponsor Protocol Number: SP0978 Start Date*: 2011-05-10
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, open-label, single-arm study to evaluate hormone and lipid levels in male subjects with partial onset seizures after a switch of treatment from carbamazepine as adjunctive treatment...
    Medical condition: Epilepsy: partial onset seizures.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Prematurely Ended) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-002461-12 Sponsor Protocol Number: SCO/BIA-2093-206 Start Date*: 2007-10-12
    Sponsor Name:BIAL - Portela & Ca, S.A.
    Full Title: EFFICACY AND SAFETY OF ESLICARBAZEPINE ACETATE (BIA 2-093) AS THERAPY FOR PATIENTS WITH PAINFUL DIABETIC NEUROPATHY: A DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMISED, PLACEBO-CONTROLLED, PARALLEL-GROUP, MU...
    Medical condition: adult patients with painful diabetic neuropathy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012680 Diabetic neuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) HU (Completed) CZ (Completed) AT (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001553-12 Sponsor Protocol Number: 2SMALL Start Date*: 2019-11-28
    Sponsor Name:Fundacion ONCOSUR
    Full Title: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-B...
    Medical condition: Histologically or cytologically confirmed diagnosis of extensive or limited SCLC. Progression to first-line platinum-based chemotherapy. Measurable disease according to RECIST v.1.1.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001843-29 Sponsor Protocol Number: TASTER2018 Start Date*: 2019-05-28
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: TASTER- TArgeting STEm cell Resistance An umbrella adaptive randomised multi–arm screening phase II trial for patients with 2nd/3rd generation TKI resistant chronic myeloid leukaemia
    Medical condition: Chronic myeloid leukaemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2006-004286-33 Sponsor Protocol Number: 1042-0501 Start Date*: 2007-05-11
    Sponsor Name:Marinus Pharmceuticals, Inc.
    Full Title: An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spasms.
    Medical condition: Infantile spasms
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021750 Infantile spasms LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003947-51 Sponsor Protocol Number: M14POS Start Date*: 2014-10-06
    Sponsor Name:NKI-AVL
    Full Title: Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone rece...
    Medical condition: Hormone receptor positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Temporarily Halted) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003614-14 Sponsor Protocol Number: RAINBOW Start Date*: 2019-12-16
    Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI"
    Full Title: Feasibility, efficacy and safety of rapid (within 7 days from HIV diagnosis) antiretroviral initiation strategy based on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-infected na...
    Medical condition: HIV infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10020441 Human immunodeficiency virus infection, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000386-32 Sponsor Protocol Number: F901318/0041 Start Date*: 2022-01-21
    Sponsor Name:F2G Ltd.
    Full Title: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with...
    Medical condition: invasive fungal infections due to Aspergillus spp.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-002154-32 Sponsor Protocol Number: AT2220-010 Start Date*: 2011-12-07
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: AN OPEN-LABEL MULTI-CENTER, INTERNATIONAL STUDY TO INVESTIGATE DRUG-DRUG INTERACTIONS BETWEEN AT2220 AND ALGLUCOSIDASE ALFA IN PATIENTS WITH POMPE DISEASE
    Medical condition: Pompe Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10036143 Pompe's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000044-25 Sponsor Protocol Number: 1143-201 Start Date*: 2013-07-16
    Sponsor Name:Debiopharm S.A.
    Full Title: A Phase I/II randomized study to determine the maximum tolerated dose, safety, pharmacokinetics and antitumor activity of Debio1143 combined with concurrent Chemo-Radiation Therapy in patients with...
    Medical condition: Patients with locally advanced squamous cell carcinoma of the head and neck
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000849-38 Sponsor Protocol Number: CRAD001C2223 Start Date*: 2005-08-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled multi-center study of RAD001 in combination with letrozole (Femara®) to investigate the value of adding RAD001 to letrozole as a first-line t...
    Medical condition: The treatment of advanced breast cancer aims at reducing tumor size, slowing progression and metastasis and reducing complications such as fatigue, bone fracture and hypercalcemia. Women with tumor...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000701-21 Sponsor Protocol Number: CRAD001C2222 Start Date*: 2004-11-25
    Sponsor Name:Novartis Services AG
    Full Title: A phase 2, double-blind, randomized, placebo-controlled, multi-center study assessing the value of adding RAD001 to letrozole (Femara®) as preoperative therapy of primary breast cancer in postmenop...
    Medical condition: Systemic treatment for breast cancer given when the primary tumors are still present in situ within the breast can result in large tumors being down-staged, which can allow for more conservative su...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed) DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-004462-40 Sponsor Protocol Number: TMC207-TiDP13-C208 Start Date*: 2007-12-20
    Sponsor Name:Tibotec BVBA
    Full Title: A Phase II, placebo-controlled, double-blind, randomized trial to evaluate the anti-bacterial activity, safety, and tolerability of TMC207 in subjects with sputum smear-positive pulmonary infection...
    Medical condition: Tuberculosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10044755 Tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-002042-36 Sponsor Protocol Number: ABI-H0731-202 Start Date*: 2018-08-06
    Sponsor Name:Assembly Biosciences
    Full Title: A Phase 2a, Multi-center, Double-blind, Placebo-controlled Study Evaluating ABI-H0731 + Entecavir vs Entecavir Alone for the Treatment of Viremic, HBeAg-positive Patients with Chronic Hepatitis B
    Medical condition: Chronic Hepatitis B
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003971-11 Sponsor Protocol Number: CICL670ADE03 Start Date*: 2007-04-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A one-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral ICL670 in patients diagnosed with Low and INT-1 risk Myelodysplastic Syndrome (MDS) and transfusion...
    Medical condition: myelodysplastic syndrome and transfusion-dependent iron overload
    Disease: Version SOC Term Classification Code Term Level
    8.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001141-80 Sponsor Protocol Number: POLA/ACOG1401 Start Date*: 2015-07-27
    Sponsor Name:Andrés Poveda
    Full Title: Phase Ib/II study to evaluate the efficacy and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumors
    Medical condition: Advanced or metastatic solid tumors (Phase I) Patients with potential tumors with possibly sensitivity to PARP inhibitors according to histology, or patients with molecular features (Phase II)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 03:46:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA